Is systemic activation of Sirt1 beneficial for ageing-associated metabolic disorders?

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 6-10

  Tang, Bor Luen ^a   Chua, Christelle En Lin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

AMP activated kinase (AMPK); Caloric restriction; Metabolic syndrome; Sirt1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SIRTUIN 1;

CALORIC RESTRICTION; DEGENERATIVE DISEASE; ENERGY METABOLISM; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; HUMAN; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; TISSUE SPECIFICITY;

AGING; ANIMALS; ENERGY METABOLISM; HUMANS; METABOLIC DISEASES; SIRTUIN 1; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 72949123238     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.016     Document Type: Short Survey

References (73)

1. Blander G., and Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73 (2004) 417-435
2. Denu J.M. The Sir 2 family of protein deacetylases. Curr. Opin. Chem. Biol. 9 (2005) 431-440
3. Tanner K.G., Landry J., Sternglanz R., et al. Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc. Natl. Acad. Sci. USA 97 (2000) 14178-14182
4. Tissenbaum H.A., and Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410 (2001) 227-230
5. Rogina B., and Helfand S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. USA 101 (2004) 15998-16003
6. Wood J.G., Rogina B., Lavu S., et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430 (2004) 686-689
7. Haigis M.C., and Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20 (2006) 2913-2921
8. Huang H., and Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 120 (2007) 2479-2487
9. van Leeuwen I., and Lain S. Sirtuins and p53. Adv. Cancer Res. 102 (2009) 171-195
10. Salminen A., Kauppinen A., Suuronen T., et al. SIRT1 longevity factor suppresses NF-kappaB-driven immune responses: regulation of aging via NF-kappaB acetylation?. Bioessays 30 (2008) 939-942
11. Picard F., Kurtev M., Chung N., et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776
12. Nemoto S., Fergusson M.M., Finkel T., et al. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J. Biol. Chem. 280 (2005) 16456-16460
13. Rodgers J.T., Lerin C., Haas W., et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434 (2005) 113-118
14. Cantó C., and Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 20 (2009) 98-105
15. M. Sugden, P. Caton, M. Holness, et al., PPAR control: it's SIRTainly as easy as PGC, J. Endocrinol. (2009), in press.
16. Longo V.D., and Kennedy B.K. Sirtuins in aging and age-related disease. Cell 126 (2006) 257-268
17. Guarente L. Sirtuins in aging and disease. Cold Spring Harb. Symp. Quant. Biol. 72 (2007) 483-488
18. Longo V.D. Linking sirtuins, IGF-I signaling, and starvation. Exp. Gerontol. 44 (2009) 70-74
19. Cantó C., and Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab. 20 (2009) 325-331
20. Kim D., Nguyen M.D., Dobbin M.M., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26 (2007) 3169-3179
21. B.L. Tang, Sirt1's complex roles in neuroprotection, Cell. Mol. Neurobiol. (2009), in press.
22. Tang B.L., and Chua C.E.L. SIRT1 and neuronal diseases. Mol. Aspects Med. 29 (2008) 187-200
23. Chong Z.Z., Lin S.H., Li F., et al. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways. Curr. Neurovasc. Res. 2 (2005) 271-285
24. Liu D., Gharavi R., Pitta M., et al. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromol. Med. 11 (2009) 28-42
25. Outeiro T.F., Kontopoulos E., Altmann S.M., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 (2007) 516-519
26. Green K.N., Steffan J.S., Martinez-Coria H., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 28 (2008) 11500-11510
27. Griswold A.J., Chang K.T., Runko A.P., et al. Sir2 mediates apoptosis through JNK-dependent pathways in Drosophila. Proc. Natl. Acad. Sci. USA 105 (2008) 8673-8678
28. Pallos J., Bodai L., Lukacsovich T., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17 (2008) 3767-3775
29. Li Y., Xu W., McBurney M.W., et al. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 8 (2008) 38-48
30. Deng C.X. SIRT1, is it a tumor promoter or tumor suppressor?. Int. J. Biol. Sci. 5 (2009) 147-152
31. Liu T., Liu P.Y., Marshall G.M., et al. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69 (2009) 1702-1705
32. Fulco M., and Sartorelli V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 7 (2008) 3669-3679
33. Chaudhary N., and Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 12 (2009) 431-437
34. Karagounis L.G., and Hawley J.A. The 5′ adenosine monophosphate-activated protein kinase: regulating the ebb and flow of cellular energetics. Int. J. Biochem. Cell Biol. 41 (2009) 2360-2363
35. Koo S.H., Flechner L., Qi L., et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 (2005) 1109-1111
36. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
37. Musi N., Hirshman M.F., Nygren J., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002) 2074-2081
38. Lerin C., Rodgers J.T., Kalume D.E., et al. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab. 3 (2006) 429-438
39. Rodgers J.T., Lerin C., Gerhart-Hines Z., et al. Metabolic adaptations through the PGC-1alpha and SIRT1 pathways. FEBS Lett. 582 (2008) 46-53
40. Nie Y., Erion D.M., Yuan Z., et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat. Cell Biol. 11 (2009) 492-500
41. Liu Y., Dentin R., Chen D., et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456 (2008) 269-273
42. Bronner M., Hertz R., Bar-Tana J., et al. Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor alpha by AMP-activated protein kinase. Biochem. J. 384 (2004) 295-305
43. Lee W.J., Kim M., Park H.S., et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem. Biophys. Res. Commun. 340 (2006) 291-295
44. Suwa M., Nakano H., Kumagai S., et al. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol. 95 (2003) 960-968
45. Jäger S., Handschin C., St-Pierre J., et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 104 (2007) 12017-12022
46. Gerhart-Hines Z., Rodgers J.T., Bare O., et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 26 (2007) 1913-1923
47. Cantó C., Gerhart-Hines Z., Feige J.N., et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458 (2009) 1056-1060
48. Moynihan K.A., Grimm A.A., Plueger M.M., et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2 (2005) 105-117
49. Bordone L., Motta M.C., Picard F., et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. 4 (2006) e31
50. da Silva Xavier G., Leclerc I., Varadi A., et al. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371 (2003) 761-774
51. Knutson M.D., and Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr. Rev. 66 (2008) 591-596
52. Howitz K.T., Bitterman K.J., Cohen H.Y., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003) 191-196
53. Baur J.A., Pearson K.J., Price N.L., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
54. Lagouge M., Argmann C., Gerhart-Hines Z., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006) 1109-1122
55. Ajmo J.M., Liang X., Rogers C.Q., et al. Resveratrol alleviates alcoholic fatty liver in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295 (2008) G833-G842
56. Bujanda L., Hijona E., Larzabal M., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 8 (2008) 40
57. Dasgupta B., and Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA 104 (2007) 7217-7222
58. Milne J.C., Lambert P.D., Schenk S., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450 (2007) 712-716
59. Smith J.J., Kenney R.D., Gagne D.J., et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol. 3 (2009) 31
60. Lin S.J., Defossez P.A., Guarente L., et al. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289 (2000) 2126-2128
61. McBurney M.W., Yang X., Jardine K., et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol. Cell. Biol. 23 (2003) 38-54
62. Cheng H.L., Mostoslavsky R., Saito S., et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA 100 (2003) 10794-10799
63. Boily G., Seifert E.L., Bevilacqua L., et al. SirT1 regulates energy metabolism and response to caloric restriction in mice. PloS One 3 (2008) e1759
64. Chen D., Steele A.D., Lindquist S., et al. Increase in activity during calorie restriction requires Sirt1. Science 310 (2005) 1641
65. Rodgers J.T., and Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. USA 104 (2007) 12861-12866
66. Erion D.M., Yonemitsu S., Nie Y., et al. SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc. Natl. Acad. Sci. USA 106 (2009) 11288-11293
67. Chen D., Bruno J., Easlon E., et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22 (2008) 1753-1757
68. Purushotham A., Schug T.T., Xu Q., et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9 (2009) 327-338
69. Bordone L., Cohen D., Robinson A., et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 6 (2007) 759-767
70. Pfluger P.T., Herranz D., Velasco-Miguel S., et al. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. USA 105 (2008) 9793-9798
71. Banks A.S., Kon N., Knight C., et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 8 (2008) 333-341
72. Zhang Q.J., Wang Z., Chen H.Z., et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res. 80 (2008) 191-199
73. Imai S.I. SIRT1 and caloric restriction: an insight into possible trade-offs between robustness and frailty. Curr. Opin. Clin. Nutr. Metab. Care 12 (2009) 350-356